<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168792">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00899847</url>
  </required_header>
  <id_info>
    <org_study_id>BMT201</org_study_id>
    <secondary_id>SU-04142009-2259</secondary_id>
    <nct_id>NCT00899847</nct_id>
  </id_info>
  <brief_title>Ph II of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI &amp; ATG</brief_title>
  <official_title>A Phase II Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) in Multiple Myeloma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      To evaluate the toxicity and tolerability of this tandem autologous/allogeneic transplant
      approach for patients with advanced stage multiple myeloma.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Graft-versus-host disease</measure>
    <time_frame>wo years after the last participant is enrolled.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse, Event free survival, Overall survival</measure>
    <time_frame>Two years after the study closes to accrual</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Transplantation, Homologous</condition>
  <condition>Transplantation, Autologous</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Blood and Marrow Transplant (BMT)</condition>
  <arm_group>
    <arm_group_label>Treatment (autologous-allogeneic tandem hematopoietic SCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous/Allogeneic HCT</intervention_name>
    <description>Undergo autologous hematopoietic SCT</description>
    <arm_group_label>Treatment (autologous-allogeneic tandem hematopoietic SCT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (autologous-allogeneic tandem hematopoietic SCT)</arm_group_label>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CPM</other_name>
    <other_name>CTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (autologous-allogeneic tandem hematopoietic SCT)</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>granulocyte colony-stimulating factor</other_name>
    <other_name>r-metHuG-CSF</other_name>
    <other_name>Recombinant Methionyl Human Granulocyte Colony Stimulating Factor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (autologous-allogeneic tandem hematopoietic SCT)</arm_group_label>
    <other_name>L-PAM</other_name>
    <other_name>L-phenylalanine mustard</other_name>
    <other_name>L-Sarcolysin</other_name>
    <other_name>L-Sarcolysin phenylalanine mustard</other_name>
    <other_name>L-sarcolysine</other_name>
    <other_name>phenylalanine mustard</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>Undergo allogeneic SCT</description>
    <arm_group_label>Treatment (autologous-allogeneic tandem hematopoietic SCT)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSC transplantation</other_name>
    <other_name>peripheral blood progenitor cell transplantation</other_name>
    <other_name>transplantation</other_name>
    <other_name>peripheral blood stem cell</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total nodal irradiation</intervention_name>
    <description>Undergo TLI</description>
    <arm_group_label>Treatment (autologous-allogeneic tandem hematopoietic SCT)</arm_group_label>
    <other_name>TLI</other_name>
    <other_name>total lymphoid irradiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (autologous-allogeneic tandem hematopoietic SCT)</arm_group_label>
    <other_name>ATG</other_name>
    <other_name>lymphocyte immune globulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (autologous-allogeneic tandem hematopoietic SCT)</arm_group_label>
    <other_name>ciclosporin</other_name>
    <other_name>CsA</other_name>
    <other_name>cyclosporin</other_name>
    <other_name>cyclosporin A</other_name>
    <other_name>CYSP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (autologous-allogeneic tandem hematopoietic SCT)</arm_group_label>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>nonmyeloablative allogeneic hematopoietic stem cell transplantation</intervention_name>
    <description>Undergo allogeneic SCT</description>
    <arm_group_label>Treatment (autologous-allogeneic tandem hematopoietic SCT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (autologous-allogeneic tandem hematopoietic SCT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        3.1.1 Stage II-III multiple myeloma or have progression after initial treatment of Stage I
        disease (Durie Salmon Staging). Patients with plasma cell leukemia are also included.

        3.1.2 Pathology reviewed and the diagnosis confirmed at Stanford University Medical
        Center.

        3.1.3 Age &gt; 18 years and &lt;= 75 years.

        3.1.4 Karnofsky Performance Status &gt; 70%.

        3.1.5 Corrected DLCO &gt; 60%

        3.1.6 Left ventricle ejection fraction (LVEF) &gt; 50%.

        3.1.7 ALT and AST must be &lt;= 2X normal. Total bilirubin &lt;= 2 mg/dL unless hemolysis or
        Gilbert's disease.

        3.1.8 Estimated creatinine clearance &gt; 50 ml/min.

        3.1.9 Have a related or unrelated HLA-identical donor or one antigen/allele mismatched in
        HLA-A, B, C or DRB1.

        3.1.10 Signed informed consent.

        3.3 Donor Evaluation Inclusion Criteria

        3.3.1 Age &gt;=17.

        3.3.2 HIV seronegative

        3.3.3 Donor must be capable of giving signed, informed consent

        3.3.4 No contraindication to the administration of G-CSF

        3.3.5 Willing to have a central venous catheter placed for apheresis if peripheral veins
        are inadequate.

        Exclusion Criteria:

        3.2.1 Prior allogeneic hematopoietic cell transplantation.

        3.2.2 Uncontrolled active infection.

        3.2.4 Uncontrolled congestive heart failure or angina.

        3.2.5 Pregnancy or nursing patients will be excluded from the study.

        3.2.6 Those who are HIV-positive will be excluded from the study due to high risk of
        lethal infection after hematopoietic cell transplantation.

        3.4 Donor Evaluation Exclusion Criteria

        3.4.1 Serious medical or psychological illness.

        3.4.2 Pregnant or lactating women are not eligible

        3.4.3 Prior malignancies within the last 5 years except for non-melanoma skin cancers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wen-Kai Weng</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 29, 2013</lastchanged_date>
  <firstreceived_date>May 8, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Mycophenolate mofetil</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mechlorethamine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
